At Innocan, we are revolutionizing chronic pain management with our breakthrough LPT-CBD technology, offering a safe and effective alternative to traditional treatments.

Addressing a Real Clinical Need

Chronic pain affects nearly 1 in 5 adults in the U.S. and Europe, significantly impacting their quality of life. Traditional treatments have contributed to adverse consequences, including the opioid epidemic, with over 75% of drug overdose deaths in the U.S attributed to opioids. This crisis highlights the urgent need for safer, more effective pain management solutions.

Innovative LPT-CBD Technology

Our LPT-CBD technology uses an injectable sustained-release platform for synthetic cannabidiol, providing several key advantages:

• High Bioavailability: Nearly 100% CBD bioavailability ensures maximum therapeutic effect.
• Prolonged Efficacy: A single injection offers continuous relief that can be equivalent to administering oral CBD twice a day for up to 4 weeks
• Safety: Avoids the risks associated with opioid treatments and traditional chronic pain management.

Market Impact

The global pain management market is projected to reach $109 billion by 2032, with chronic pain accounting for 58% of this market. Our LPT-CBD technology aims to capture a significant share by addressing the unmet needs of millions suffering from chronic pain.

Preclinical and Clinical Successes

Our LPT-CBD technology has shown promising results in preclinical and observational studies conducted on various animal models:

• Goats: Provided significant pain relief resulting from paralysis and improved well-being
• Donkey: Provided immediate pain relief and improved mobility for an amputee suffering from Laminitis
• Mini Pigs: Demonstrated excellent drug tolerance with no adverse events
• Rabbits: Showed prolonged CBD exposure from a single injection, supporting data from studies in other animals

Regulatory Progress

We are advancing through the FDA review process [link to Pipeline], presenting our preclinical findings and plans for IND-enabling studies and Phase 1 clinical trials.

Commitment to Advancing Human Health

We are dedicated to improving human health through scientific innovation. Our LPT-CBD platform addresses real clinical needs, enhancing the lives of those suffering from chronic pain. 

Discover how Innocan is setting new standards in pain management with our groundbreaking LPT-CBD technology.